PTPRD and non-small cell lung carcinoma: In Rizvi2018 cohort, PTPRD mutation were significantly associated with better PFS, and the median PFS in PTPRD mutant-type vs. wild-type NSCLC patients were 5.6 months vs. 3.1 months (P=0.04).